Galapagos NV

Galapagos NV is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Galapagos NV is not very popular among insiders. Galapagos NV is a good stock to invest in, but there are better stocks to choose.
Log in to see more information.
Galapagos NV is a biotechnology company, which engages in the identification and development of smal...
GLPG Fundamental Data by TradingView

News

Galapagos NV (NASDAQ:GLPG) to Post FY2024 Earnings of $0.08 Per Share, Leerink Partnrs Forecasts
Galapagos NV (NASDAQ:GLPG) to Post FY2024 Earnings of $0.08 Per Share, Leerink Partnrs Forecasts

Zolmax Galapagos NV (NASDAQ:GLPG - Free Report) - Investment analysts at Leerink Partnrs issued their FY2024 earnings estimates for Galapagos in a note issued to investors on Monday, September 9th...\n more…

Galapagos NV to Post FY2024 Earnings of $0.08 Per Share, Leerink Partnrs Forecasts (NASDAQ:GLPG)
Galapagos NV to Post FY2024 Earnings of $0.08 Per Share, Leerink Partnrs Forecasts (NASDAQ:GLPG)

Ticker Report Galapagos NV (NASDAQ:GLPG - Free Report) - Research analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Galapagos in a note issued to investors on Monday, September 9th...\n more…

Signaturefd LLC Acquires 1,258 Shares of Galapagos NV (NASDAQ:GLPG)
Signaturefd LLC Acquires 1,258 Shares of Galapagos NV (NASDAQ:GLPG)

Zolmax Signaturefd LLC boosted its stake in Galapagos NV (NASDAQ:GLPG - Free Report) by 48.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange...\n more…

Galapagos receives transparency notification from FMR LLC
Galapagos receives transparency notification from FMR LLC

Globe Newswire Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency...\n more…

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Globe Newswire Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information inside information Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has...\n more…

Galapagos receives transparency notification from FMR LLC
Galapagos receives transparency notification from FMR LLC

Globe Newswire Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency...\n more…